Drug Profile
Research programme: CNS disease therapies - ImClone/Neurome
Latest Information Update: 26 Mar 2009
Price :
$50
*
At a glance
- Originator ImClone Systems; Neurome
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 28 Sep 2004 Preclinical trials in CNS disorders in USA (unspecified route)